Ministry of Health of Vietnam requires hospitals to increase collection and treatment in the face of the current increasing COVID-19 situation?
Statistics of the number of Covid-19 cases in the beginning of April 2023?
On April 17, 2023, the Ministry of Health of Vietnam issued Official Dispatch No. 2213/BYT-KCB in 2023 on strengthening the collection and treatment of Covid-19 cases.
Accordingly, in Official Dispatch No. 2213/BYT-KCB in 2023, the Covid-19 situation in early April 2023 was mentioned as follows:
- In 7 days from April 5, 2023 to April 11, 2023, the whole country recorded 639 new cases, an average of 90 new cases per day, through the analysis of 639 new cases, 193 cases were recorded (accounting for 30 cases). .2%) in the group of 50 years and older, the number of hospitalizations tends to increase and there have been 10 severe cases.
- Only 3 days of April 14, 15 and 16, 2023, 2272 new cases were recorded, an average of 757 cases per day.
Ministry of Health of Vietnam requires hospitals to increase collection and treatment in the face of the current increasing COVID-19 situation?
Requesting hospitals to increase collection and treatment before the current COVID-19 situation in Vietnam?
Pursuant to Official Dispatch No. 2213/BYT-KCB in 2023, the Ministry of Health has made requirements to proactively respond to the epidemic situation to ensure the effective collection, emergency, care and treatment of COVID-19 patients, the Ministry of Health of Vietnam requires:
- Review and update the plan of collecting and treating COVID-19 patients of the province and the unit according to the principle of 4 on the spot.
- Assign the number of hospital beds to treat COVID-19 patients specifically to each unit; arrange human resources to monitor, care for and treat COVID-19 patients when hospitalized.
- Prepare drugs, equipment and medical supplies in accordance with the plans for collection and treatment of COVID-19 patients when the epidemic may develop complicatedly.
- Actively improve treatment capacity, especially focusing on improving the capacity of emergency and active resuscitation at health facilities:
+ Coordinate with the medical oxygen coordination department of the province and city to ensure the supply of medical oxygen for the treatment needs of COVID-19 patients at health facilities.
+ Implement training to reiterate guidelines for diagnosis and treatment of COVID-19 for healthcare workers.
+ Strengthen consultations at hospitals, consult with higher levels for professional advice, minimize the transfer of patients to higher levels.
+ For cases beyond their professional capacity, when transferring to a hospital, they must consult and contact a higher-level hospital before transferring and ensure the safety of the transferred patient.
- In treatment facilities, strengthen infection control and infection prevention measures to minimize the spread of disease in the hospital, especially strengthen the protection of patients in high-risk groups (such as pregnant women, people with underlying diseases, the elderly, ...), the intensive care unit, cardiology, artificial kidney, surgery....
At the same time, strengthen the cleaning of the outside, the hygiene of the wards, arrange the arrangement of the wards conveniently, suitable to the epidemic situation and ensure a green, clean and beautiful environment.
- For severe cases, suspected cases of COVID-19 located in Hospitals, when rapid antigen test results are negative but still suspect COVID-19 it is recommended to perform PCR test to diagnose COVID-19 to avoid missing cases to spread the disease.
- Provincial and last-level hospitals for COVID-19 treatment need to monitor and clinically evaluate current hospitalized severe COVID-19 cases and send gene sequencing test to assess severity and criticality and report to the Ministry of Health of Vietnam for consideration and adjustment of professional guidelines.
How does the Ministry of Health of Vietnam prescribe drugs to treat Covid-19?
Pursuant to Table 2, subsection 6.2, Section 6 attached to Decision No. 437/QD-BYT in 2022 guiding the use of Remdesivir and Molnupiravir drugs as follows:
Active ingredient | Indication | Contraindication | Dose | Note |
Remdesivir | - Patients receiving inpatient treatment, having mild infection, and having at least one risk factor; having moderate and severe infection, having developed the conditions in less than 10 days which include respiratory distress and requiring supplemental oxygenation, high-flow nasal cannula (HFNC), non-invasive ventilation - Recommended for use in combination with corticoid (prioritizing dexamethason) - Patients who have taken remdesivir prior to being subject to invasive ventilation or ECMO may continue using remdesivir to the full regimen. | - Patients having previous anaphylaxis to any component of the drugs - Patients having ALT liver enzyme 5 times above the upper limit of normal value | + Persons ≥ 12 years of age and weighing > 40 kg: 200 mg for the first day , 100 mg/day for subsequent days, one session of intravenous infusion for 30 - 120 minutes + Treatment duration: 5 days, if patients are not clinically improved, another 5-day treatment can be needed. | - For children < 12 years of age, comply with guidelines for diagnosing and treating COVID-19 in children - Pregnant and breastfeeding women: Insufficient data. Not recommended unless the gains drastically outweigh the risks. - Monitor patients during infusion period and for 1 hour after infusion to promptly respond to allergic reaction and infusion reaction (if any). - Monitor liver enzyme during drug use period. Stop taking drugs if ALT liver enzyme is 5 times above the upper limit of normal value - Data is insufficient to recommend the drug for patients whose eGFR < 30 mL/minute. - For more details, refer to drug instruction manual |
Molnupiravir | - COVID-19 patients of at least 18 years of age or older, having mild to moderate infection, and having at least one risk factor. - Drug is to be taken within 5 days of developing symptoms or getting positive test results. Patients requiring hospitalization who have previously taken molnupiravir can continue taking molnupiravir to complete 5-day regimen depending on decision on admitting physician. | Patients having anaphylaxis to molnupiravir or any component thereof. | 800 mg/time, 2 times/day. - Treatment period: 5 days | - Not recommended for pregnant women, breastfeeding women, children under 18 years of age due to the drug’s risk of toxin for the fetus, bone, cartilage. - Women capable of pregnancy and women in reproductive age should take appropriate contraceptive methods during treatment and for 4 days after taking the last dose of molnupiravir - Breastfeeding women: breastfeeding is not recommended during treatment period and for 4 days after taking the last dose of molnupiravir - For male in reproductive age, use appropriate and effective contraceptive methods during treatment period and for at least 3 months after taking the last dose of molnupiravir - For more details, refer to drug instruction manual approved by Ministry of Health |
LawNet
